Kiromic BioPharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kiromic BioPharma sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Kiromic BioPharma: 2 sponsored US clinical trials, 1 recruiting.
Kiromic BioPharma sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bone Metastases From Solid Tumors, with 1 trials.
Mid-pack sponsor footprint
Kiromic BioPharma is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
NCT06069570
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
NCT02224599
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Kiromic BioPharma pipeline
1 recruiting of 2 indexed (50% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Bone Metastases From Solid Tumors (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kiromic BioPharma: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Kiromic BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Kiromic BioPharma page
2 registered trials is a research-attention snapshot, not an endorsement of Kiromic BioPharma or any single study.
- 1 of Kiromic BioPharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bone Metastases From Solid Tumors is the condition Kiromic BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bone Metastases From Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kiromic BioPharma pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.